Stage IIIA of squamous lung cancer is stage IIIA of squamous lung cancer, and the 5-year survival rate of stage IIIA of squamous lung cancer is about 36%. Its specific survival period can be differentiated by factors such as timing of treatment, treatment mode, physical quality, etc. There is no uniform standard. Lung squamous carcinoma belongs to non-small cell lung cancer, and in lung cancer TNM staging, stage III of lung squamous carcinoma can be categorized into stage ⅢA, ⅢB and ⅢC. Stage IIIA belongs to middle and late stage squamous lung cancer, and the treatment is mainly based on surgery, supplemented by radiotherapy, targeted therapy, immunotherapy, vascular targeted therapy and so on. Among them, chemotherapy needs to be applied systemically before and after surgery in order to achieve better therapeutic effect. After standardized treatment, the 5-year survival rate of patients can reach about 36%. Compared with other pathological types, immunotherapy is more effective for squamous lung cancer. Immunotherapy combined with first-line chemotherapy regimen can usually prolong the survival of patients. Patients should actively cooperate with the treatment under the guidance of their doctors in order to prolong survival and improve the quality of life. There is a certain risk of recurrence of the disease, so after being discharged from the hospital after treatment, patients with stage IIIA squamous lung cancer should be rechecked every 3-6 months in the first 3 years, once a year in the next 4-5 years, and once a year for more than 5 years. At the same time, they should develop good living habits, pay attention to the monitoring of their condition, and seek medical treatment in time when any abnormality occurs.